GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results

Clinical trial NCT06310382 · UNKNOWN

Trial details

NCT number: NCT06310382
Sponsor: Suzhou Genhouse Bio Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors With MAPK Signal Pathway Mutations

Start date: 2022-12-07
Primary completion: 2025-05-26
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.